Liraglutide

Liraglutide was approved by FDA (US) in 2010 as hypoglycemic subcutaneous drug. Liraglutide is a glucagon like peptide 1 (GLP-1) receptor agoinst. Liraglutide increases intracellular Cyclic AMP leading to insulin release in the presence of elevated glucose concentration.Liraglutide also decreases glucagon secretion and delays in gastric emptying time which resluts in lowering of blood glucose. Liraglutide is indicated for type II Diabetes Mellitus patients adjunct to diet and excercise to improve glycemic control

Brands
Adult Dose
Dose: 0.6 to 1.8 mg/ml
Single Dose: 1.2 (1.2)
Frequency: 1 hourly
Route: SC
Instructions: initiate at 0.6 mg/ day for 1 week .
Neonatal
Paedriatic
Characteristics
. It is of Semi Synthetic origin and belongs to analog of human GLP-1. It belongs to Hypoglycaemics pharmacological group on the basis of mechanism of action. The Molecular Weight of liraglutide is 3751.20. It is weakly alkaline drug.
Contraindications
liraglutide is contraindicated in conditions like Thyroid cancer.
Effects
liraglutide produces potentially life-threatening effects which include Angioedema, Urticaria. which are responsible for the discontinuation of liraglutide therapy.The signs and symptoms that are produced after the acute overdosage of liraglutide include Nausea & vomiting.The symptomatic adverse reactions produced by liraglutide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Diarrhea, Constipation, Rashes, Erythema, Nausea and vomiting, Hypertension, Sinusitis, Hypoglycemia, Back pain, Nasopharyngitis, Injection site reactions, influenza, urinary tract infection.
Indications
liraglutide is primarily indicated in conditions like Diabetes mellitus type-ii.
Interactions
No data regarding the interactions of liraglutide was found.
Interfrence
Risks
Drug should not be given to patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Risk of thyroid cell tumors Serious hypoglycemia can occur when ligragutide is given with an insulin Risk of Pancreatitis
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.